Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing a new class of medicines. These medicines target genetically determined dependencies within the chromatin regulatory system using Foghorn's proprietary Gene Traffic Control® Platform. This platform provides an integrated, mechanistic understanding of how various components of the chromatin regulatory system interact, allowing the identification, validation, and potential drugging of targets within the system.
The company's lead programs include FHD-286 and FHD-609. FHD-286 is a small-molecule enzymatic inhibitor of BRG1 and BRM, targeting acute myeloid leukemia (AML) and uveal melanoma. FHD-609 is a protein degrader of BRD9 aimed at treating synovial sarcoma. Additionally, Foghorn is developing preclinical and discovery programs such as selective BRM targeting non-small-cell lung cancer and selective ARID1B modulators for bladder, ovarian, and endometrial cancer.
Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company's financial stability is reflected in its cash and equivalents of approximately $259.9 million as of September 30, 2023, which supports its robust pipeline and strategic objectives for 2024 and beyond.
Recent Achievements and Current Projects:
- Initiated a Phase 1 combination study of FHD-286 in AML with data expected in the second half of 2024.
- Progress with the selective BRM inhibitor FHD-909, with an IND planned for the second quarter of 2024, primarily targeting non-small cell lung cancer.
- Presented preclinical data showcasing selective CBP and EP300 degrader programs, demonstrating significant tumor growth inhibition without associated hematopoietic toxicity.
- Announced multiple strategic milestones, including financial updates and corporate outlooks, reflecting continued progress across various therapeutic programs.
The company remains committed to advancing its preclinical and clinical programs, supported by collaborations and financial investments, with the goal of developing novel medicines that can transform the lives of patients with serious diseases.
Foghorn Therapeutics (FHTX) provided a corporate and financial update for Q2 2022. The Phase 1 study of FHD-286 in metastatic uveal melanoma is progressing, while a partial clinical hold by the FDA affects its use in AML and MDS. Initial clinical data for FHD-609 in synovial sarcoma is expected in 2023. The company achieved a research milestone under its Merck collaboration, triggering a $5 million payment. As of June 30, 2022, Foghorn reported $394.7 million in cash and equivalents, indicating strong financial health.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in key investor conferences throughout August 2022, focusing on oncology and the innovative Gene Traffic Control platform. Key events include virtual meetings on August 8 and a panel discussion at the 13th Annual Wedbush PacGrow Healthcare Conference on August 9 at 10:20 a.m. ET. Foghorn is advancing a pipeline of drug candidates that target genetically determined dependencies, with two currently in clinical studies. A webcast of the panel will be available for up to 90 days after the event.
Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in three upcoming investor conferences. The focus is on its Gene Traffic Control® Platform, which aims to innovate oncology treatments. Key events include:
- Cowen's 3rd Annual Oncology Innovation Summit on June 2 at 10:30 a.m. ET.
- Jefferies Healthcare Conference on June 8 at 1:30 p.m. ET.
- Goldman Sachs 43rd Annual Global Healthcare Conference on June 13 at 3:20 p.m. PT.
Webcasts will be available via the company's website post-event.
Foghorn Therapeutics (Nasdaq: FHTX) announced that the FDA has placed a partial clinical hold on its Phase 1 study of FHD-286 in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), following a report of a death linked to potential differentiation syndrome. While existing patients can continue treatment, new patient enrollment is halted until the issue is resolved. This hold does not affect the ongoing FHD-286 study for metastatic uveal melanoma. The company is suspending guidance on data release timing for the AML/MDS study.
Foghorn Therapeutics (FHTX) continues to advance its pipeline with three phase 1 studies targeting the chromatin regulatory system. Initial clinical data for FHD-286 is anticipated in H2 2022, focusing on cancers such as AML and uveal melanoma, while FHD-609 aims for data in 2023. Recent preclinical findings at AACR highlight FHD-286's anti-tumor activity. The company reported a strong balance sheet with $424.7 million in cash as of March 31, 2022, supporting ongoing development efforts.
Foghorn Therapeutics (FHTX) presented promising preclinical data on its dual inhibitor, FHD-286, at the 2022 AACR Annual Meeting. Targeting the chromatin regulatory system, FHD-286 shows potential in treating cancer, particularly acute myeloid leukemia (AML) and metastatic uveal melanoma. Key findings include significant anti-tumor activity in AML models and favorable combination effects with existing therapies. The data support ongoing Phase 1 trials and underscore FHTX's innovative Gene Traffic Control platform aimed at transforming cancer treatment.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting from April 8-13, 2022, in New Orleans. The company will present preclinical data for FHD-286, a novel BAF inhibitor targeting cancers like acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS), and metastatic uveal melanoma (UM). The oral presentation is set for April 11, showcasing the pharmacological profile and anti-tumor properties of FHD-286. The late-breaking poster on April 13 will address the modulation of SPI1 transcriptional programs related to AML.
Foghorn Therapeutics (Nasdaq: FHTX) will participate in the 2022 Guggenheim Targeted Protein Degradation Day on March 16, 2022, at 9:30 a.m. ET. The event will be held virtually, featuring a fireside chat that highlights Foghorn's innovative work in oncology through its Gene Traffic Control platform. The webcast will be accessible on their website for 90 days following the event. Foghorn focuses on discovering medicines that address genetically determined dependencies in the chromatin regulatory system, with multiple oncology product candidates currently in clinical studies.
Foghorn Therapeutics (FHTX) provided a corporate update highlighting key achievements from 2021 and strategic priorities for 2022. The company reported a significant cash position of $454.3 million following a collaboration with Lilly, which included $380 million in upfront payments. Initial clinical data for its drug candidates, FHD-286 and FHD-609, is expected in the first half of 2022. Foghorn continues to advance its therapeutic pipeline targeting various cancers through its Gene Traffic Control® platform, enhancing its portfolio of oncology treatments.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in Cowen’s 42nd Annual Health Care Conference, scheduled from March 7th to March 9th, 2022. The company will be featured in a panel addressing leukemias and myeloproliferative neoplasms on March 7th at 10:30 a.m. ET. Foghorn is engaged in developing innovative medicines that target genetic dependencies in the chromatin regulatory system, having multiple oncology product candidates, with two in clinical studies. A webcast of the panel will be available for 90 days post-event on their website.
FAQ
What is the current stock price of Foghorn Therapeutics (FHTX)?
What is the market cap of Foghorn Therapeutics (FHTX)?
What is Foghorn Therapeutics Inc. focused on?
What are the main products under development by Foghorn Therapeutics?
What is the Gene Traffic Control® Platform?
What are some of the recent achievements of Foghorn Therapeutics?
What is Foghorn Therapeutics' financial condition?
Who are Foghorn Therapeutics' collaborators?
When was Foghorn Therapeutics founded?
Where is Foghorn Therapeutics headquartered?
What are Foghorn Therapeutics' key areas of research?
What is the strategic outlook for Foghorn Therapeutics in 2024?
